Maybe that will give them time to come up with a partner based on the interim results.
17th Oct 2013
The Company believes that this data could be very useful in planning for the future development of ATL1103 beyond this Phase II trial. Depending on the outcomes of the interim analysis, these results may also provide sufficient information to expedite discussions with prospective pharmaceutical and development partners on ATL1103 ahead of the final trial results which, as per previous guidance, are anticipated in Q2’14.
One for Sam and Itsa, when was the last time in any company document that partnership for 1103 was mentioned?
23rd Dec 2013
Based on these interim results, the Company will be following up interest from pharmaceutical companies in partnering the development of ATL1103 for Phase III clinical trials.”
Ann: Allowance of Canadian Patent on ATL1103 & Development Update, page-4
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $83.73M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 7.9¢ | $153.8K | 1.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 927041 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 218878 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |